Fannkoer Biotech (Zhongshan) Co., Ltd. announced the completion of a Series B financing round exceeding RMB 100 million (USD 14.5 million), co-led by a renowned investment institution and Hecheng Capital, with participation from Fengyang Jialu, Zhongshan Jianzhuo, and Zhongzhi Pharma. Existing shareholders Sheng Lianxing and Renxi Fund also increased their stakes. The proceeds will fund radiopharmaceutical platform construction and accelerate clinical trials, advancing the company’s InnoRDC (Radionuclide Drug Conjugate) pipeline through investigator-initiated trials (IITs) in ~100 cancer patients.
IIT expansion to 200+ patients; registrational trial design
2026-2027
Pipeline Advancement
Lead asset IND submission; additional RDC candidates to clinic
2027
Partnership
Big Pharma licensing discussions; global rights monetization
Data-dependent (2027-2028)
Forward‑Looking Statements This brief contains forward‑looking statements regarding Findcure Bio’s radiopharmaceutical platform construction, IIT clinical outcomes, and RDC pipeline advancement. Actual results may differ due to radioisotope supply constraints, regulatory requirements for radiopharmaceutical manufacturing, and competitive dynamics with Novartis and domestic radiopharma developers.-Fineline Info & Tech
Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.
